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Background: HPV 16 is the cause of cervical carcinoma, but only a small fraction of women with HPV infection
progress to this pathology. Besides persistent infection and HPV integration, several studies have suggested that
HPV intratype variants may contribute to the development of cancer. The purpose of this study was to investigate
the nucleotide variability and phylogenetically classify HPV 16 E6 variants circulating over a period of 16 years in
women from Southern Mexico, and to analyze its association with precursor lesions and cervical carcinoma.
Methods: This study was conducted in 330 cervical DNA samples with HPV 16 from women who were residents of
the State of Guerrero, located in Southern Mexico. According of cytological and/or histological diagnosis, samples
were divided into the following four groups: no intraepithelial lesion (n = 97), low-grade squamous intraepithelial
lesion (n = 123), high-grade squamous intraepithelial lesion (n = 19) and cervical carcinoma (n = 91). HPV 16 E6 gene
was amplified, sequenced and aligned with reference sequence (HPV 16R) and a phylogenetic tree was constructed
to identify and classify HPV 16 variants. Chi squared was used and data analysis and statistics were done with SPSS
Statistics and STATA softwares.
Results: Twenty seven HPV 16 E6 variants were detected in women from Southern Mexico, 82.12% belonged to the EUR,
17.58% to AA1 and 0.3% to Afr2a sublineages. The most common was E-G350 (40%), followed by E-prototype (13.03%),
E-C188/G350 (11.82%), AA-a (10.61%), AA-c (6.07%) and E-A176/G350 (5.15%). Eight new E6 variants were found and 2 of
them lead to amino acid change: E-C183/G350 (I27T) and E-C306/G350 (K68T). The HPV 16 variant that showed the greatest
risk of leading to the development of CC was AA-a (OR = 69.01, CI = 7.57-628.96), followed by E-A176/G350 (OR = 39.82,
CI = 4.11-386.04), AA-c (OR = 21.16, CI 2.59-172.56), E-G350 (OR = 13.25, CI = 2.02-87.12) and E-C188/G350 (OR = 10.48,
CI = 1.39-78.92).
Conclusions: The variants more frequently found in women with cervical carcinoma are E-G350, AA-a, AA-c, E-C188/
G350 and E-A176/G350. All of them are associated with the development of cervical carcinoma, however, AA-a showed
the highest association. This study reinforces the proposal that HPV 16 AA-a is an oncogenic risk for cervical carcinoma
progression in Mexico.
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Infection by high risk human papillomavirus (HR-HPV)
is necessary for the development of cervical carcinoma
(CC) [1] and HPV 16 is the cause of more than half of
CC worldwide [2]. Only a small fraction of women with
HPV infection may progress to cervical carcinoma; how-
ever, the factors that favor this progression are still
poorly understood. Besides persistent infection and HPV
integration [3,4], several studies have suggested that
HPV intratype variants may contribute to cancer devel-
opment [4-7].
Like other HR-HPV, HPV 16 has well preserved distinct-
ive intratypic variants by geographical origin [8], their global
distribution and risk of cervical carcinoma appears to be
dependent on the population [9,10]. Its phylogeny reflects
evolutionary divergence associated with human migration
patterns, suggesting that they may have co-diversified as hu-
man populations expanded worldwide [11]. HPV 16 variants
have been classified into 4 major lineages and 9 sublineages
based on common LCR and E6 single polymorphisms: (1)
European-Asian (EAS), including European (EUR) and
Asian (As) sublineages; (2) African 1 (AFR1), including
Afr1a and Afr1b sublineages; (3) African 2 (AFR2), including
Afr2a and Afr2b sublineages; and (4) Asian American/North
American (AA/NA), including Asian American 1 (AA1),
Asian American 2 (AA2) and North American (NA) subli-
neages [12].
Several reports have shown the presence of common poly-
morphisms that generate amino acid changes in the E6
oncoprotein, one of them is T350G, and is present in the
four lineages. T350G causes a leucine to valine change
(L83V), that leads to the split of the EUR sublineage into
three classes, 350 T (prototype sequence), 350C and 350G.
Other polymorphisms including A131G, G132C, C143G,
G145T, G176A, T178G and C335T generate the amino acid
changes R10G/I, Q14H/D, D25E/N, I27R and H78Y, re-
spectively [13]. It has been suggested that these polymor-
phisms and the subsequent amino acid changes in E6 HPV
16 variants may influence the persistence of HPV infection
and its progression to cervical carcinoma [4,14-18].
Epidemiologic data shows that regions with high inci-
dence of cervical carcinoma like Latin America, Africa
and Asia, also have a high prevalence of sublineages AA
and Af [9]. Studies in Mexico have reported that persistent
infection and risk of progression to cervical carcinoma is
higher when HPV infection is caused by AA sub-lineages
compared with EUR sublineages [5,19-21].
Social disparities like access to social security health care
services, ethnic groups, residence and socioeconomic level
are factors associated with cervical carcinoma develop-
ment [22]. The State of Guerrero, located in Southern
Mexico, is the second poorest state in Mexico and a ma-
jority of inhabitants have a very low socioeconomic level.
In this region, cervical carcinoma is the most commontype of cancer in women and has the fourth highest mor-
tality rate in the country with 12.5 deaths per 100,000
women, compared to the national mortality rate of 9.1 per
100,000 in 2008 [23].
We have previously shown that HPV 16 was the most
commonly identified HPV genotype in cervical carcinoma
and high grade squamous intraepithelial lesions in women
from the State of Guerrero. We studied a sample of HPV
16 positive women and found E and AA variants [24]. It
has been proposed that variants AA of HPV 16 are more
oncogenic than E variants [5,25].
Knowing the regional variants of HPV 16 is of great
value for evolutionary, phylogenetic, epidemiological and
biological analysis [13]. To further analyze the regional
variants of HPV 16, the aim of this study was to investi-
gate the nucleotide variability and phylogenetically clas-
sify HPV 16 E6 variants circulating over a period of
16 years in the Southern Mexican population, and to
analyze its association with the whole spectrum of dis-
ease from no intraepithelial lesion in cervical epithelium
to cervical carcinoma.
The most dominant HPV variants were detected in low
and high-grade squamous intraepithelial lesion, cervical
carcinoma and no intraepithelial lesion, and 8 novel HPV
16 variants were found. An association between E-G350,
E-A176/G350, E-C188/G350, AA-a and AA-c variants
and the risk of developing cervical carcinoma was shown
in this study.
Results
HPV 16 E6 variants and phylogenetic analysis
The variant analysis for the E6 gene was carried out in 330
HPV16 samples from all study groups. Using the HPV 16 R
(Los Alamos National Laboratory, http://www.ncbi.nlm.nih.
gov/nuccore/NC_001526.2) as a reference sequence, a total
of 27 variants were detected, 8 of them were new. Sequence
analysis showed substitution in 29 nucleotides located be-
tween positions 104 and 559 in the E6 sequence with a pre-
dicted amino acid change (Table 1).
The phylogenetic analysis showed that the E6 variants
found belong to EUR, AA1 and Afr2a sublineages. Six of
the 8 novel variants were related to variants of the EUR sub-
lineages, and 2 to variants of the AA1 sublineage (Figure 1).
The phylogenetic classification of the E6 variants
showed that the majority (82.12%) belonged to the EUR
sublineage, followed by AA1 (17.58%) and Afr2a (0.3%)
sublineages. From sublineage EUR, 15.45% was class E-
T350 which includes E-Prototype (13.03%), and 66.67%
was class E-G350 finding 19 subclasses. From sublineage
AA1, AA-a class was the most frequent (10.91%) followed
by AA-c class (6.67%). From the 27 variants found in this
study, the most common E6 variant was E-G350 (40%),
followed by E-prototype (13.03%), E-C188/G350 (11.82%),
AA-a (10.61%), AA-c (6.07%) and E-A176/G350 (5.15%).
Table 1 Phylogenetic classification, nucleotide sequence variations and frequency of HPV-16 E6 variants identified in women from Southern Mexico
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E-G350 - - - - - - - - - - - - - - - - - - - - G - - - - - L83V 132 40.00%
E-C109/
G350
c - - - - - - - - - - - - - - - - - - - G - - - - - L83V 6 1.82%
E-G110/
G350
- G - - - - - - - - - - - - - - - - - - G - - - - - Q3E/L83V 2 0.61%
E-G131/
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E-A176/
G350




- - - - - - A - - - - - - - - - - - - - G - g - - - D25N/L83V 1 0.30%
E-T182/
G350
- - - - - - - T - - - - - - - - - - - - G - - - - - I27L/L83V 4 1.21%
E-C182/
G350
- - - - - - - C - - - - - - - - - - - - G - - - - - I27L/L83V 2 0.61%
**E-C183/
G350
- - - - - - - - C - - - - - - - - - - - G - - - - - I27T/L83V 3 0.91%
E-G185/
G350
- - - - - - - - - G - - - - - - - - - - G - - - - - L28V/L83V 2 0.61%
E-A188/
G350
- - - - - - - - - - A - - - - - - - - - G - - - - - E29K/L83V 1 0.30%
E-C188/
G350



















- - - - - - - - - - - G t - - - - - - - G - - - - - E29G/L83V 1 0.30%
E-G257/
G350
- - - - - - - - - - - - - G - - - - - - G - - - - - I52L/L83V 1 0.30%
**E-C306/
G350
- - - - - - - - - - - - - - - - - C - - G - - - - - K68T/L83V 1 0.30%
E-C442/
G350
- - - - - - - - - - - - - - - - - - - - G - - C - - L83V/E113D 1 0.30%
**G535/
G350
- - - - - - - - - - - - - - - - - - - - G - - - - g L83V 1 0.30%
Lineage AA/NA/Sublineage AA1
Class AA-a 36 10.91%
AA-a - - - - - T - - - - - - - - - a g - - T G - - - g - Q14H/H78Y/L83V 35 10.61%
**AA-a/
C188
- - - - - T - - - - C - - - - a g - - T G - - - g - Q14H/E29Q/
H78Y/L83V
1 0.30%
Class AA-c 22 6.67%




















c - - T G T - - - - - - - - - a g - - T - g - - - - R10I/Q14D/H78Y 1 0.30%
HPV 16 R: reference sequence. Predicted amino acid change: the amino acid numeration was done using the 151 amino acid E6 oncoprotein form as reference. Capital letters indicate polymorphisms that produce











Figure 1 Phylogenetic tree based in E6 variations of HPV 16. To classify the newly identified variants, their phylogenetic relationship with
previously reported variants were determined, by constructing a phylogenetic tree based on E6 sequences found in Southern Mexico. The new
variants are underlined. The tree is drawn to scale with branch lengths measured in the number of substitutions per site. The analysis involved 27
nucleotide sequences. All positions containing gaps and missing data were eliminated. There were a total of 456 positions in the final dataset.
Analyses were conducted in MEGA5.2 [43].
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G-350, one is subclass of class AA-a and the last one is sub-
class of class AA-c (Table 1). E-C183/G350, E-C306/G350
and E-G535/G350 show polymorphisms that so far have not
been reported, E-C183/G350 leads to the amino acid change
I27T, E-C306/G350 changes K68T and E-G535/G350 does
not lead to any amino acid change (Table 1).HPV 16 E6 variants in cervical carcinoma and
precursor lesions
A total of 330 samples with HPV16 were analyzed. The hist-
ology of the 91 cervical carcinoma identified 76 (83.5%) as
squamous cell carcinoma (SCC), 13 (14.3%) as adenocarcin-
oma (ADC) and 2 (2.2%) as other epithelial tumors. The
majority of cases of cervical carcinomas were found in the
FIGO stage IIB (34%). Additionally, 19 samples were HSIL,
123 LSIL and 97 with non-IL (11 with inflammation and 86
with normal Pap smears).HPV 16 AA variants were more common in ADC
(46.15%) than in SCC (30.27%). AA-a variants increased
their frequency according to the degree of evolution of cer-
vical lesion: 38.46% in ADC, 15.79% in SCC, 15.79% in
HSIL, 8.94% in LSIL and 3.09% in non-IL. HPV 16 E vari-
ants were the most common in SCC (69.75%), HSIL
(78.94%), LSIL (87.79%) and non-IL (89.69%). HPV 16 E-
G350 class was the most frequent in all groups, E-Prototype,
on the other hand, was not detected in ADC and other epi-
thelial tumors, and only 2.63% of SCC, 5.26% of HSIL,
18.7% of LSIL and 17.53% of non-IL (Table 2). The Af vari-
ants were not found in any cervical carcinoma.
Associations between the five most frequent HPV 16
E6 variants and LSIL, HSIL and cervical carcinoma were
assessed (Table 3), using the HPV 16 E-Prototype as a
reference. The 5 variants analyzed showed significant
association with CC, but only AA-a variant showed sig-
nificant association with HSIL. The HPV 16 variant that
showed the most risk of developing CC was AA-a (OR
Table 2 Distribution of HPV 16 E6 variants for diagnostic category
Variant Non-IL N=97 LSIL N=123 HSIL N=19 SCC N=76 ADC N=13 Other Epithelial Tumor N=2 Cervical carcinoma N=91 Total N=330
E variants 87 (89.69%) 108 (87.79%) 15 (78.94%) 53 (69.75%) 7 (53.84%) 1 (50.0%) 61 (67.05%) 271 (82.12%)
Class E-T350 23 (23.72%) 23 (18.7%) 1 (5.26%) 4 (5.26%) - - 4 (4.4%) 51 (15.45%)
E-Prototype 17 (17.53%) 23 (18.7%) 1 (5.26%) 2 (2.63%) - - 2 (2.2%) 43 (13.03%)
E-G131 6 (6.19%) - - 2 (2.63%) - - 2 (2.2%) 8 (2.42%)
Class E-G350 64 (65.97%) 85 (69.09%) 14 (73.68%) 49 (64.49%) 7 (53.84%) 1 (50.0%) 57 (62.65%) 220 (66.67%)
E-G350 39 (40.21%) 56 (45.53%) 6 (31.58%) 28 (36. 84%) 3 (23.08%) - 31 (34.07%) 132 (40.00%)
E-C109/G350 - 3 (2.44%) 1 (5.26%) 2 (2.63%) - - 2 (2.2%) 6 (1.82%)
E-G110/G350 1 (1.03%) 1 (0.81%) - - - - - 2 (0.61%)
E-G131/G350 1 (1.03%) - - 1 (1.32%) - - 1 (1.1%) 2 (0.61%)
E-G131/C188/G350 1 (1.03%) 1 (0.81%) - - - - - 2 (0.61%)
E-A176/G350 3 (3.09%) 5 (4.07%) 1 (5.26%) 5 (6.58%) 2 (15.38%) 1 (50.0%) 8 (8.79%) 17 (5.15%)
**E-A176/G424/G350 - - - 1 (1.32%) - - 1 (1.1%) 1 (0.30%)
E-T182/G350 - 1 (0.81%) 1 (5.26%) 2 (2.63%) - - 2 (2.2%) 4 (1.21%)
E-C182/G350 1 (1.03%) 1 (0.81%) - - - - - 2 (0.61%)
**E-C183/G350 3 (3.09%) - - - - - - 3 (0.91%)
E-G185/G350 1 (1.03%) - - 1 (1.32%) - - 1 (1.1%) 2 (0.61%)
E-A188/G350 - - - 1 (1.32%) - - 1 (1.1%) 1 (0.30%)
E-C188/G350 11 (11.34%) 13 (10.57%) 5 (26.32%) 8 (10.53%) 2 (15.38%) - 10 (10.99%) 39 (11.82%)
**E-C188/G310/G350 1 (1.03%) 1 (0.81%) - - - - - 2 (0.61%)
**E-G189/T256/G350 - 1 (0.81%) - - - - - 1 (0.30%)
E-G257/G350 - 1 (0.81%) - - - - - 1 (0.30%)
**E-C306/G350 1 (1.03%) - - - - - - 1 (0.30%)
E-C442/G350 1 (1.03%) - - - - - - 1 (0.30%)
**G535/G350 - 1 (0.81%) - - - - - 1 (0.30%)
AA variants 10 (10.31%) 14 (11.38%) 4 (21.05%) 23 (30.27%) 6 (46.15%) 1 (50.0%) 30 (32.97%) 58 (17.58%)
Class AA-a 4 (4.12%) 11 (8.94%) 3 (15.79%) 12 (15.79%) 5 (38.46%) 1 (50.0%) 18 (19.78%) 36 (10.91%)
AA-a 3 (3.09%) 11 (8.94%) 3 (15.79%) 12 (15.79%) 5 (38.46 %) 1 (50.0%) 18 (19.78%) 35 (10.61%)
**AA-a/C188 1 (1.03%) - - - - - - 1 (0.30%)
Class AA-c 6 (6.19%) 3 (2.44%) 1 (5.26%) 11 (14.48%) 1 (7.69%) - 12 (13.19%) 22 (6.67%)











Table 2 Distribution of HPV 16 E6 variants for diagnostic category (Continued)
**AA-c/G185 - - - 1 (1.32%) - - 1 (1.1%) 1 (0.30%)
AA-c/C271 - - - 1 (1.32%) - - 1 (1.1%) 1 (0.30%)
Af variants - 1 (0.81%) - - - - - 1 (0.30%)
Class Af2-a - 1 (0.81%) - - - - - 1 (0.30%)
Af2-a/C109/G403 - 1 (0.81%) - - - - - 1 (0.30%)




































Class E-T350a 23 (23.71%) 23 (18.7%) - 1 (5.26%) - 4 (5.26%) - 0 (0%)b - 0 .0%) 4 (4.40%) -
E-Prototype 17 (17.53%) 23 (18.7%) 1* 1 (5.26%) 1* 2 (2.63%) 1* 0 (0%)b 1* - 2 (2.2%) 1*
Class E-G350 64 (65.98%) 85 (69.11%) 0.97 3.73 12.66 2.42 14.12
0.47-1.99 14 (73.68%) 0.46-30.44 49 (64.47%) 1.89-84.92 7 (53.85%) 0.25-∞ 1 0.0%) 57 (62.65%) 2.19-90.97
0.94 0.22 0.009 0.44 0.005
E-G350 39 (40.21%) 56 (45.53%) 1.01 2.58 12.56 1.74 13.25
0.47-2.17 6 (31.58%) 0.29-23.17 28 (36.84%) 1.84-85.86 3 (23.08%) 0.15-∞ - 31 (34.07%) 2.02-87.12
0.98 0.39 0.010 0.65 0.007
E-A176/G350 3 (3.09%) 5 (4.07%) 1.49 5.82 24.79 12.62 39.82
0.31-7.23 1 (5.26%) 0.28-121.37 5 (6.58%) 2.33-263.35 2 (15.38%) 0.79-∞ 1 0.0%) 8 (8.79%) 4.11-386.04
0.62 0.26 0.008 0.07 0.001
E-C188/G350 11 (11.34%) 13 (10.57%) 1.0 7.91 8.56 3.05 10.48
0.35-2.84 5 (26.32%) 0.81-77.58 8 (10.53%) 1.07-68.26 2 (15.38%) 0.23-∞ - 10 (10.99%) 1.39-78.92
0.99 0.08 0.043 0.40 0.023
Class AA-a 4 (4.12%) 11 (8.94%) 2.18 12.65 35.21 21.24 54.51
0.58-8.17 3 (15.79%) 1.02-156.20 12 (15.79%) 3.87-320.39 5 (38.46%) 1.75-∞ 1 0.0%) 18 (19.78%) 6.36-467.62
0.25 0.048 0.002 0.016 0.000
AA-a 3 (3.09%) 11 (8.94%) 3.08 17.40 43.73 26.69 69.01
0.73-13.04 3 (15.79%) 1.32-229.60 12 (15.79%) 4.55-420.56 5 (38.46%) 2.10-∞ 1 0.0%) 18 (19.78%) 7.57-628.96
0.13 0.03 0.001 0.01 0.000
Class AA-c 6 (6.19%) 3 (2.44%) 0.44 2.79 24.46 3.01 25.28
0.10-2.06 1 (5.26%) 0.15-52.20 11 (14.47%) 2.89-207.12 1 (7.69%) 0.15-∞ - 12 (13.19%) 3.12-204.74
0.30 0.49 0.003 0.47 0.002
AA-c 6 (6.19%) 3 (2.44%) 0.46 2.93 19.97 2.99 21.16
0.10-2.15 1 (5.26%) 0.16-54.90 9 (11.84%) 2.34-170.25 1 (7.69%) 0.15-∞ - 10 (10.99%) 2.59-172.56
0.32 0.47 0.006 0.47 0.004
Class Af2-a 0 (0%) 1 (0.81%) - 0 (0%) - 0 (0%) - 0 (0%) - 0 %) 0 (0%) -
*,Indicate reference category (E-Prototype).
a ,OR was not calculated for E-T350 class because it includes reference category (E-Prototype).
b,To calculate OR and CI in ADC an artificial case was created.
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(OR = 39.82, CI = 4.11-386.04), AA-c (OR = 21.16, CI
2.59-172.56), E-G350 (OR = 13.25, CI = 2.02-87.12) and
E-C188/G350 (OR = 10.48, CI = 1.39-78.92).
The novel HPV 16 E6 variants were found in 11
women, 6 from the center of the State of Guerrero, 2
from the coast and 3 from Northern Guerrero. These
variants were found in samples taken from 1997 to 2012.
The AA-a/C188 HPV 16 variant was found in non-IL
cervical sample taken in 1997, AA-c/G185 variant was
found in a cervical carcinoma sample taken in 1998, E-
A176/G424/G350 was found in a cervical carcinoma
sample taken in 2003, E-C183/G350 was found in a
non-IL cervical samples taken in 2002 and 2006, E-
C306/G350 was found in non-IL a cervical sample taken
in 2003, E-C188/G310/G350 was found in a non-IL cer-
vical sample taken in 2004 and an LSIL taken in 2009,
E-G535/G350 was found in an LSIL cervical sample
taken in 2006 and E-G189/T256/G350 variant was found
in an LSIL cervical sample taken in 2008. Six novel vari-
ants were found with non-IL, 3 with LSIL and 2 with
cervical carcinoma (E-A176/G350/G424 and AA-c/
G185). Data from a follow up cytological diagnosis of 5
women with HPV 16 E6 novel variants were collected.
Follow up information shows that two with the variant
E-C183/G350 evolved from non-IL to LSIL, whereas
those with E-C188/G310/G350 and E-G189/T256/G350
maintain LSIL status (Table 4).
Sequence Data
The 8 novel variant sequences described in this report
have been deposited in GenBank under designated acces-
sion numbers KJ465992, KJ465993, KJ465994, KJ465995,
KJ465996, KJ465997, KJ465998 and KJ465999.
Discussion
The objective of this study was to document HPV 16 E6
variants circulating over a period of 16 years in women
from Southern Mexico and to analyze its association
with cervical carcinoma and precursor lesions. Accord-
ing to sequence analysis, nucleotide polymorphisms
were detected and used to investigate the intratypic
heterogeneity of HPV 16 in the Southern Mexican
population.
It is known that the genomes of HPV 16 variants differ
geographically worldwide due to evolution linked to ethnic
groups and that the risk for cervical carcinoma seems to be
population-dependent [5,6,8,10,26-28]. Mexico is a country
with diverse ethnic origins because European immigrants
mixed with various indigenous populations, in consequence
current population carries HPV variant from various ethnic
group [8]. In the present study of 330 women with HPV 16
sampled over a period of 16 years, 27 variants were found; E
variants were the most common, followed by AA variants.Studies worldwide have found that E variants are the most
prevalent worldwide (94% in Oceania, 84% in Eastern Asia,
83% in North America, 82% in Europe, 78% in Western Asia
and 71% in Central and South America) with exception of
Africa (36%) [9]. Tornesello, et al. (2011) showed that glo-
bally, the most prevalent variant in Central and South
America (including Mexico) is E-G350 (43%) followed by
AA (30%) and E-Prototype (27%). In North America it is E-
Prototype and E-G350 (49% each one) followed by AA
(11%). In Europe it is E-G350 (44%) followed by E-
Prototype (38%) and AA (6%). In Western Asia it is E-G350
(51%) followed by E-Prototype (25%) and AA (9%). In East-
ern Asia it is As (42%) followed by E-Prototype (37%) and
E-G350 (9%). In Oceania it is E-Prototype (38%) followed by
E-G350 (29%) and As (12%) and in Africa it is Afr1 and
Afr2 (62%) followed by E-Prototype (34%). In the present
study, the most frequently identified HPV 16 variant was E-
G350 (40%), following the E-Prototype (13.03%), E-C188/
G350 (11.82%), AA-a (10.61%), AA-c (6.07%) and E-A176/
G350 (5.15%). However, unlike other regions, it was found
that E-Prototype frequency in Southern Mexico is lower
than the rest of the world, while E-G350, considering all its
subclasses together, is more frequent than in the rest of the
world. The AA variants of HPV 16 were 15-fold more
prevalent than E-prototype in cervical carcinoma.
Studies on HPV 16 variants in Mexico have shown
that even in the same country its distribution is different
depending on the region analyzed. The prevalence of
HPV 16 variants, stratified by histological groups, from
five geographical regions of Mexico (Central, North-
Central, Northeastern, Southeastern and Southern) is
presented in Table 5. The E variants are the most preva-
lent in all geographical regions in women, E-prototype
in the Southeastern region and E-G350 in Central and
Southern Mexico. AA variants are present in the five re-
gions, but its prevalence is higher in the Northeastern
region than in the rest of the country, although it is
inhabited mostly by Europeans descendants, Mestizo
and very few indigenous ethnic groups [5,8,20,21,23,29].
The State of Guerrero, located in Southern Mexico, is
inhabited by Mestizo, Nahuas, Mixtecs, Amuzgos, Tla-
panecos and Afro-Mexicans. In this study, which is lar-
ger than our previous study [24], we found that HPV 16
E-G350 was the most common variant in all histological
grades, although in ADC, the prevalence of E-G350 and
AA is close. In all regions of Mexico, the prevalence of
AA in ADC tends to increase in comparison to the other
histological grades. Moreover, among AA variants, AA-a
is more common than AA-c.
Of the 27 HPV 16 variants found in Southern Mexico in
16 years, 8 of them were new and may be considered to be
variants specific to this Mexican region.
Previous data suggests that HPV 16 variants with E6 se-
quence variation are biologically distinct and may confer
Table 4 Novel HPV16 E6 variants, regional distribution, collection year and lesion in cervical epithelium




Diagnosis/Sampling year Follow up Diagnosis/Year
1 E-A176/G424/G350 KJ465994 G424 - Atoyac/Coast Cervical carcinoma 2003 -
2 E-C183/G350 KJ465995 C183 I27T Chilpancingo/Center Non-IL 2002 LSIL 2006
3 E-C183/G350 KJ465995 C183 I27T Chilpancingo/Center Non-IL 2006 LSIL 2009
4 E-C183/G350 KJ465995 C183 I27T Chilpancingo/Center Non-IL 2002 -
5 E-C188/G310/G350 KJ465996 G310 - Chilpancingo/Center Non-IL 2004 Non-IL 2005
6 E-C188/G310/G350 KJ465996 G310 - Chilpancingo/Center LSIL 2009 LSIL 2012
7 E-G189/T256/G350 KJ465998 G189 and T256 - Chilpancingo/Center LSIL 2008 LSIL 2009
8 E-C306/G350 KJ465997 C306 K68T Acapulco Coast Non-IL 2003 -
9 E-G535/G350 KJ465999 G535 - Tepecoacuilco/North LSIL 2006 -
10 AA-a/C188 KJ465992 C188 - Iguala/North Non-IL 1997 -











Table 5 Published data on HPV 16 variants distribution in cervical epithelium lesions in regions of Mexico
Region of Mexico State/City Genome region Samples Histology HPV 16 E HPV 16 E-Prototype HPV 16 E-G350 AA AA-a AA-c Reference
Central Mexico City E6, L1 80 SCC 56% 4% 52% 44% - - Berumen, et al., 2001
6 ADC 0% 0% 0% 100% - -
20 Non-IL 90% 5% 85% 10% - -
Central Mexico City E6 50 SCC 30% - - 40% 32% 8% Lizano, et al., 2006
11 ADC 55% - - 45% 27% 18%
23 HSIL 74% - - 26% 26% 0%
13 LSIL 54% - - 46% 46% 0%
16 Non-IL 56% - - 44% 44% 0%
North-Central San Luis Potosí E6 2 ICC 100% 50% 50% 0% 0% 0% López-Revilla, et al., 2009
9 HSIL 89% 33% 56% 11% 11% 0%
27 LSIL 96% 85% 11% 4% 4% 0%
Northeastern Nuevo León LCR 112 Undefined 13% - - 87% - - Calleja-Macias, et al., 2004
Southeastern Yucatan E6 25 IIC 52% 28% 24% 44% - - González-Losa, et al. 2004
15 LSIL 100% 66% 33% 0% 0% 0%
Southern Guerrero E6 45 ICC 67% - - 33% - - Illades-Aguiar, et al., 2010
10 HSIL 90% - - 10% - -
18 LSIL 67% - - 33% - -
5 Non-IL 60% - - 40% - -
Southern Guerrero E6 76 SCC 70% 3% 64% 30% 16% 14%
13 ADC 54% - 54% 46% 38% 8%
19 HSIL 79% 5% 74% 21% 16% 5% Present study
123 LSIL 88% 19% 69% 11% 9% 2%
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intraepithelial lesions and invasive cervical carcinoma. E6
specific sequence variations may modify its linkage to cellu-
lar targets changing its ability for p53 degradation, inhibiting
keratynocyte differentiation, modifying signal transduction
[30-34].
It was proposed that there might be a strong relation be-
tween AA variant and cervical carcinoma development
[9,16,25,35,36]. Using a comparative analysis, it was found in
this study that HPV 16 AA-a detection rate increased ac-
cording to the severity of the cervical lesion, with a large in-
crease in ADC. The results show that HPV 16 AA-a
infection has a strong association with a high risk of CC de-
velopment compared to E-Prototype. This study reinforces
the proposal that HPV 16 AA-a is an oncogenic risk for cer-
vical carcinoma progression in Mexico [5]. Similar behavior
was observed in HPV 16 E-A176/G350 variant, the rate in-
creased according severity of the cervical lesion, although
frequency was less than for AA-a, and the infection is asso-
ciated with a risk for development of CC compared with
E-Prototype, but less than for AA-a. AA-c, E-G350 and
E-C188/G350, also show association with risk for CC com-
pared with E-Prototype, although lower than the aforemen-
tioned. The results of this study highlight the importance of
identifying HPV 16 variants in the screening of clinical sam-
ples and of conducting follow up test for women with the
HPV 16 AA-a variant.
According to the HPV variants found in this study, the
amino acid substitutions circulating in Southern Mexico
are: Q3E, R10G, Q14H, D25N, I27L, I27R I27T, L28V,
E29K, E29Q, E29G, I52L, K68T, F69L, H78Y, L83V (the
most frequent) and E113D. The amino acid substitutions
present in the HPV 16 E6 variants in descending order
of association with CC were: Q14R/H78Y/L83V (AA-a
variant), D25N/L83V (E-A176/G350 variant), Q14R/I27/
H78Y/L83V (AA-c variant), L83V (E-G350 variant) and
E29Q/L83V (E-C188/G350 variant). Q14R/H78Y/L83V
amino acid changes gender AA variants with increased
oncogenic potential and more efficient evasion of the
host’s immune surveillance [25,37,38]. L83V amino acid
change display more efficient degradation of Bax and
binding to E6AP, induces ubiquitination and degradation
of p53, NFX1-91 and PDZ proteins [14,33]. D25N, I27R
and E29Q amino acid changes affect E6 T cell epitope
[33]. Two of the 8 novel variants found in this study had
amino acid changes not previously reported: I27T in E-
C183/G350 variant and K68T in E-C306/G350 variant.
I27T amino acid change is located at the N-terminal do-
main of the E6 oncoprotein; K68T is located between zinc
fingers of E6. The E-C183/G350 variant was found in
women with non-IL who progressed to LSIL. The finding
of this new variant could be potentially important.
It was not possible to analyze the association of novel E6
variants for the risk of developing cervical carcinomabecause of the low number of positive samples; however,
by having nucleotide changes may also be associated with
the development of cervical carcinoma.
Conclusions
Current findings show that in 16 years, at least 27 HPV 16
E6 variants were present in Southern Mexico and 8 novel
variants were found, which may be considered to be vari-
ants specific to this Mexican region. The variants more
frequently found in women with cervical carcinoma are E-
G350, AA-a, AA-c, E-C188/G350 and E-A176/G350. All
of them are associated with the development of cervical
carcinoma, however, AA-a showed the highest association.
This study reinforces the proposal that HPV 16 AA-a is
an oncogenic risk for cervical carcinoma progression in
Mexico. This represents the largest study carried out in
Mexico analyzing all classes of European and non-
European variants in the whole spectrum of disease, from
intraepithelial lesion-free cytology to cervical carcinoma
including squamous cell carcinoma and adenocarcinoma.
Further studies are needed to clarify the pathogenicity of
HPV 16 E6 variants.
Methods
Samples
The database and biobank, with 7,480 cervical DNA
samples collected from 1997 to 2012, of the Molecular
Biomedicine and Cytopathology Laboratories at the
School of Chemistry and Biology of the Autonomous
University of Guerrero in Chilpancingo Guerrero,
Mexico, was searched for all cervical DNA samples with
HPV 16 and 330 were found in appropriate conditions
for analysis. The samples were studied to investigate cir-
culating HPV 16 variants in Southern Mexico and to do
a comparative analysis between these variants and the
different grades of cervical lesion.
Cervical samples came from women who were residents
of State of Guerrero, seeking cytological screening or for
other gynecological complaints, which attended public
health centers of Acapulco, Chilpancingo, and Iguala, the
three biggest cities in this state of Southern Mexico. Based
on the diagnosis, samples were divided into: (1) no intrae-
pithelial lesion (non-IL) (n = 97), (2) low-grade squamous
intraepithelial lesion (LSIL) (n = 123), high-grade squamous
intraepithelial lesion (HSIL) (n = 19) and (4) cervical carcin-
oma (CC) (n = 91). Non-IL and LSIL samples have cyto-
logical diagnosis; HSIL and CC samples have histological
diagnosis. Cytological diagnosis was done according to the
Bethesda System [39] and histological diagnosis according
to the classification system of the International Federation
of Gynecology and Obstetrics (FIGO) [40].
This study was approved by the Bioethical Committee
the Autonomous University of Guerrero. Informed con-
sent was obtained from women participants.
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depending on the year of in which the sample was taken
and analyzed: (1) from 1997 to 2010, HPV detection was
done by the MY09/11 system and typing by restriction frag-
ment length polymorphism (RFLPs); (2) from 2005 to 2010,
detection was done by general GP5+/6+ PCR system and
typing by sequencing analysis [24] when samples analyzed
with MY09/11 PCR were negative; (3) from 2010 to 2012
HPV was detected and typed with INNO Lipa genotyping
Extra (Innogenetics) [41].HPV variants
The HPV 16 E6 gene was amplified using type-specific
primers E6-F048 (5′GAACCGAAACCGGTTAGTAT3′)
and E6-R622 (5′CAGTTGTCTCTGGTTGCAAA3′)
that amplify a 575-bp region [19]. PCR amplification
was carried out in a 50 μl reaction containing 1 μM of
each primer, 4 mM of MgCl2, and 1.25 U of Platinum
Taq DNA Polymerase (Invitrogen). The DNA amplifica-
tion was done in a DNA Eppendorf AG 22331 Hamburg
[24] as follows: initial denaturation at 95°C for 10 min,
followed by 40 cycles of 95°C for 45 s, 57°C for 30 s, 72°C
for 1.15 min, and a final extension al 72°C for 10 min.
PCR products were purified with 75% isopropanol (2–34
protocol of user manual of Applied Biosystems) and ZR
DNA Sequencing Clean-up Kit™ (ZYMO RESEARCH).
These were sequenced using Big Dye Terminator Chemistry
v3.1 Ready Reaction Kit (Applied Biosystems, Foster City,
CA) in an automated sequencer DNA ABI Prism 310 Gen-
etic Analyzer (Applied Biosystems, Foster City, CA) using
primers previously described [19]. Sequences were ana-
lyzed with EMBOSS Stretcher of the European Institute
of Bioinformatics, LALING GENESTREAM network ser-
ver (http://www.ebi.ac.uk/Tools/psa/emboss_stretcher/
nucleotide.html and http://embnet.vital-it.ch/software/
LALIGN_form.html) and the Finch TV program re-
spectively. Sequences were aligned with reference se-
quence (HPV 16R) [8]. Using the E6 sequence, HPV 16
variants were classified into lineages with their respect-
ive sublineages [12]. The sublineages were stratified in
classes and subclasses [13]. When new polymorphisms
were found, independent PCRs were carried out under
the described conditions. The products obtained were
sequenced on both strands to exclude PCR artifacts and
to validate the polymorphism found and accept them as
new variants.Phylogenetic analysis
HPV 16 E6 sequences were compared by multiple se-
quence alignments using the CLUSTAL W method [42].
A phylogenetic tree was constructed by neighbor-joining
analysis executed by MEGA 5.2 program [43].Statistical analysis
The Chi squared test was used to compare HPV 16 variant
frequencies and cervical lesion grade. Differences were con-
sidered to be statistically significant when p values were less
than 0.05. Age-adjusted odds ratios and 95% confidence in-
tervals were used to estimate associations. Data analysis and
statistics were done using IBM SPSS Statistics V.22.0 and
STATAV.11 softwares.
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